Osteoarthritis Management: The Next Generation

0
205
canine osteoarthritis management
Antinol® RAPID is the latest advancement in our multimodal approach to canine osteoarthritis management.

This article is sponsored content brought to you by Cenvet.

Antinol® RAPID is the latest advancement in our multimodal approach to canine osteoarthritis management, offering veterinarians an effective and safe long-term option.

Since its launch in Australia back in 2018, Antinol® has become a keystone in osteoarthritis management protocols for hundreds of veterinary practices, with over 800 clinics in Australia now stocking it. 

With the ever-increasing popularity of Antinol®, we have recently announced the next generation: Antinol® RAPID! Over the past few months, most veterinarians have switched to the new Antinol® RAPID formulation, which had been years in development and has surpassed all expectations.

Antinol® RAPID is the latest advancement in our multimodal approach to canine osteoarthritis management, offering veterinarians an effective and safe long-term option. The active ingredient consists of two components. The first is PCSO-524® (the main active in Antinol®), a marine lipid compound extracted from Green Lipped Mussel Powder via a patented process called Supercritical Fluid Extraction. PCSO-524® is then mixed with a proprietary high-phospholipid krill extract via the same process, creating a patented active compound known as EAB-277™.

While PCSO-524® and krill extracts are effective anti-inflammatory compounds in their own right, laboratory studies have proven that the synergistic blend of EAB-277™ in Antinol® RAPID represents a more potent anti-inflammatory combination, more effective than either product alone. 

As a nutraceutical, Antinol® is amongst the most researched and published non-drug compound in veterinary medicine today, with two separate force-plate analysis studies demonstrating similar efficacy against NSAIDs with no associated side effects1,2. Research is ongoing, with investigations into other indications for skin, cognitive and respiratory support being a priority. 

Decades of published peer-reviewed research firmly establishes Antinol® and Antinol® RAPID as superior to other natural joint products. 

Antinol® RAPID has an excellent safety track record, with no documented side effects and no known contraindications. It can therefore be used in a versatile fashion, to be combined with NSAIDs, injectables or other pharmaceuticals and supplements for enhanced case management options and long-term patient support. 

Veterinarians have also shared some successful off-label uses for Antinol® RAPID. Due to the unique combination of lipids and absence of any allergenic proteins in EAB-277™, the product is being applied by veterinarians to manage skin and coat health as well as other inflammatory conditions. The use of Antinol® in cats has also been reported by veterinarians, especially as an alternative or adjunctive therapy for NSAIDs in many patients. Antinol® use in cats is considered off-label in Australia, but is used widely in overseas markets.  

Antinol® RAPID also comes with a 45 day 100% money-back guarantee for satisfaction and palatability.

Over the past years, pet owners have been so impressed with Antinol® that stories of their pets and how Antinol® had changed their lives forever have been popping up all over social media. You can read more about some of these success stories on the Antinol® Facebook page (facebook.com.au/Antinol.au).

Antinol® RAPID is breaking new ground and delivering even better results for veterinarians and pet owners alike. Antinol® RAPID remains proudly a veterinary exclusive product and unlike the original it has no human equivalent.

Want to learn more about Antinol® RAPID? Email antinol@cenvet.com.au, or call 1300 CENVET.

Visit Cenvet


References:

1. Kwananocha, I., Vijarnsorn, M., Kashemsant, N. and Lekcharoensuk, C., 2016. Effectiveness of disease modifying osteoarthritis agents and carprofen for treatment of canine osteoarthritis. Thai Journal of Veterinary Medicine, 46(3), pp.363-371.

2. Vijarnsorn, M., Kwananocha, I., Kashemsant, N., Jarudecha, T., Lekcharoensuk, C., Beale, B., Peirone, B. and Lascelles, B., 2019. The effectiveness of marine based fatty acid compound (PCSO-524) and firocoxib in the treatment of canine osteoarthritis. BMC Veterinary Research, 15(1).

LEAVE A REPLY

Please enter your comment!
Please enter your name here